Latest Reports

The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking. 

It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations. 

This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment. 

The “2026 IOL Market Report” delivers a comprehensive, data-driven view of the global intraocular lens market, combining detailed analysis of today’s landscape with five-year forecasts designed to inform strategy, investment, and competitive positioning. 

Built on Market Scope’s proprietary models and deep industry insight, the report identifies the trends shaping demand, tracks shifts in technology adoption, and highlights the factors that will define success in an increasingly competitive and innovation-driven market. 

The analysis segments the market across 11 distinct IOL categories—commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs— to provide a clear view of where growth is occurring and how the premium market continues to evolve. 

In addition, the report profiles 40 leading companies, offering insight into their product portfolios, strategic positioning, competitive strengths, and future outlook to provide you with the intelligence needed to benchmark competitors and identify opportunities in the global IOL market. 

Market Scope’s "2026 Retinal Disease Model" delivers deep, country-level insight into the true scale of retinal disease worldwide, with detailed prevalence estimates and five-year forecasts by age group for every country with a population over one million.

Built on the latest clinical research and global demographic projections, this proprietary model provides a rigorous, forward-looking view of retinal disease—and can be customized by geography and disease category to match specific strategic needs. The model enables companies to quantify addressable patient populations, evaluate target markets for clinical- and commercial-stage products, and understand how disease volume and demographics are expected to evolve over time.

Market Scope’s "2026 Glaucoma Disease Model" offers extensive country-level prevalence data and five-year forecasts for glaucoma by type and by age group for all countries with a population over a million.

This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients’ diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.

Market Scope’s “2026 Ophthalmic Diagnostic Equipment Market Report” provides a comprehensive view of the global market for ophthalmic diagnostic technologies. The report examines current markets for diagnostic equipment used in ophthalmic surgery, refracting and screening instruments, and emerging technologies. It also includes five-year global forecasts and detailed regional and economic analysis across the US, Western Europe, Japan, other wealthy nations, China, India, Latin America, and developing markets worldwide. 

The report evaluates more than 800 devices from 115 manufacturers, spanning a broad range of technologies, including corneal topographers, anterior eye scanners, biometers, tonometers, fundus cameras, perimeters, refractors, slit lamps, and advanced microscopy systems. 

Dedicated sections for each equipment category provide detailed market sizing, pricing trends, competitor market share, installed equipment base, and company profiles. Together, these insights give manufacturers, investors, and eye care providers a clear picture of the competitive landscape, where the market is headed, and the technologies and opportunities likely to shape ophthalmic diagnostics over the next five years. 

The “2026 Glaucoma Surgical Device Market Report” provides a comprehensive analysis of the global glaucoma surgical device market, examining the technologies, clinical trends, competitive landscape, and market forces shaping the future of glaucoma surgery across every major region.

The report explores global glaucoma prevalence, treatment patterns, and the continued evolution of surgical care. It provides in-depth coverage of commercially available devices—including trabecular meshwork (TM) bypass stents, subconjunctival shunts, canal surgery devices, suprachoroidal devices, and tube shunts—while also assessing emerging technologies and investigational products expected to influence future treatment strategies and market growth.

Detailed market forecasts through 2031 provide unit and revenue projections across major device categories, procedure types, and geographic markets. The report also features competitive market share analysis, adoption trends, and comprehensive profiles of leading manufacturers and emerging innovators, providing a clear view of the companies and technologies driving the next phase of the glaucoma surgical device market.

The "2026 Exudative Retinal Disease Pharmaceuticals Market Report" provides a comprehensive analysis of the global market for anti-VEGF therapies and emerging treatments for exudative retinal diseases. The report examines the competitive landscape, evolving treatment patterns, reimbursement dynamics, and key market forces shaping the sector, with five-year forecasts in both units and revenue for branded anti-VEGFs, off-label oncology therapies, biosimilars, sustained drug delivery platforms, and next-generation therapeutics. 

Extensive market segmentation and regional analysis are combined with in-depth profiles of key competitors, covering their product portfolios, commercialization approaches, pipeline progress, and overall market positioning. Taken together, this analysis gives manufacturers, investors, and other stakeholders a clear understanding of how the market is evolving today and where the most meaningful growth opportunities are likely to emerge over the next five years. 

Market Scope has published the Ophthalmic Market Perspectives (OMP) newsletter for more than 20 years. The newsletter provides the latest business information that is shaping ophthalmic markets and professions. Our articles explore new technologies and company developments. We offer opinions on issues facing the industry. We also analyze and chart quarterly industry data, and we forecast market performance over time.

The “2026 Nonexudative Retinal Disease Pharmaceuticals Market Report” provides a comprehensive analysis of current and emerging therapies for geographic atrophy, dry AMD, and other nonexudative retinal diseases. It examines complement inhibitors, gene therapies, sustained-release technologies, antioxidants, and other evolving treatment approaches, along with key market trends, patient economics, reimbursement dynamics, and five-year growth forecasts. 

The report also features detailed unit and revenue projections, market share estimates by product category, and profiles of 19 leading competitors, including insights into their strategies, pipelines, and future outlooks. 

The "2026 Refractive Error Model" delivers comprehensive country-level prevalence estimates and five-year forecasts for five refractive error categories, segmented by age group across every country with a population exceeding one million.

Built on the latest clinical research, demographic trends, and proprietary forecasting methodology, the model provides a robust foundation for evaluating global market opportunities. Available as a customizable dataset by geography and disease category, it helps organizations assess target markets, quantify addressable patient populations, support commercial planning, and prioritize clinical and product development strategies with confidence.